EHA Library - The official digital education library of European Hematology Association (EHA)

EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL
Author(s): ,
Tim H Brümmendorf
Affiliations:
Universitätsklinikum RWTH Aachen,Aachen,Germany
,
Frank Giles
Affiliations:
Developmental Therapeutics Consortium,Chicago,United States
,
Carlo Gambacorti-Passerini
Affiliations:
University of Milano-Bicocca,Monza,Italy
,
Gail J Roboz
Affiliations:
Department of Hematology/Oncology, Weill Cornell Medicine,New York, NY,United States
,
Philipp Le Coutre
Affiliations:
Charité-Universitätsmedizin Berlin,Berlin,Germany
,
Henrik Hjorth-Hansen
Affiliations:
Department of Hematology, St. Olavs Hospital, Norwegian University of Science and Technology,Trondheim,Norway
,
Leif Stenke
Affiliations:
Department of Hematology, Karolinska University Hospital, and Department of Medicine, Karolinska Institutet,Stockholm,Sweden
,
Francisco Cervantes
Affiliations:
Hospital Clinic, IDIBAPS, University of Barcelona,Barcelona,Spain
,
Philippe Rousselot
Affiliations:
Service d'Hématologie et Oncologie, Hôpital de Versailles, Université Versailles Saint Quentin en Yvelines,Le Chesnay,France
,
Andrea Viqueira
Affiliations:
Pfizer SLU,Madrid,Spain
,
Nathalie Bardy-Bouxin
Affiliations:
Pfizer International Operation-Oncology,Paris,France
,
Eric Leip
Affiliations:
Pfizer Inc,Cambridge, MA,United States
,
Jocelyn M Leone
Affiliations:
Pfizer Inc,Cambridge, MA,United States
,
Juan L Steegmann
Affiliations:
Hematology Department & IIS-IP, Hospital Universitario de la Princesa,Madrid,Spain
,
Jorge E Cortes
Affiliations:
University of Texas MD Anderson Cancer Center,Houston, TX,United States
Andreas Hochhaus
Affiliations:
Klinik für Innere Medizin II, Universitätsklinikum Jena,Jena,Germany
EHA Library. H Brümmendorf T. 06/14/19; 266215; PF415
Tim H Brümmendorf
Tim H Brümmendorf
Contributions
Abstract

Abstract: PF415

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background
Bosutinib (BOS) is approved in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are newly diagnosed (400 mg once daily [QD]) or resistant or intolerant to prior treatment (tx; 500 mg QD). Some pts require dose interruptions/reductions to manage the occurrence of adverse events (AEs).

Aims
Evaluate efficacy and safety of BOS before and after dose reductions in pretreated pts with Ph+ chronic phase (CP) CML.

Methods
BYOND is an ongoing, single-arm, open-label phase 4 study of BOS in pts resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). Dose reduction to 400, 300 or 200 mg QD was allowed for management of tx-related AEs.

Results
Pts with Ph+ CP CML (N=156) were categorized as resistant to ≥1 prior TKI (n=83; 53.2%) or intolerant to all prior TKIs (73; 46.8%); data cutoff: 1 y after last enrolled pt. Overall, median (range) tx duration was 23.7 (0.2–42.2) mo and median (range) dose intensity was 313.1 (79.7–560.6) mg/d. In resistant and intolerant pts, median (range) tx duration was similar: 23.4 (0.2–42.2) and 25.3 (0.4–41.9) mo, respectively. 37.3% resistant and 63.0% intolerant pts experienced dose reductions to 300 or 200 mg QD. This resulted in higher median dose intensity in resistant vs intolerant pts: 405.9 (125.0–560.6) vs 292.0 (79.7–500.0) mg/d. 153 pts started at 500 mg QD or reduced to a lower dose, ≥1 dose reduction to 400, 300 and 200 mg QD, respectively, was seen in 42 (27.5%), 39 (25.5%) and 38 (24.8%) and median (range) tx duration was 27.6 (0.4–42.2), 11.1 (0.8–41.3) and 24.0 (0.9–41.9) mo. Of 34 pts who remained on 500 mg QD without dose reduction, median (range) tx duration was 23.5 (0.2–41.4) mo; 21 (61.8%) had complete cytogenetic response; 19 (55.9%) had major molecular response (MMR). Among pts who dose-reduced, most had a newly attained or maintained response, few pts lost a previously attained response (Table). Of 10 pts with baseline mutations, 7 (70.0%) received 400 or 500 mg QD; 3 (30.0%) achieved at least MMR. Across all time points up to 2 y, a high proportion (>65%) of resistant pts still receiving tx were on 400 or 500 mg QD while ~20% of intolerant pts still receiving tx were on 500 mg QD. Tx was discontinued in 17 (50.0%), 12 (28.6%), 24 (61.5%) and 15 (39.5%) pts without dose reduction, ≥1 dose reduction to 400, 300 and 200 mg QD, respectively, including: 4 (11.8%), 7 (16.7%), 17 (43.6%), 11 (28.9%) due to AEs; and 5 (14.7%), 0, 2 (5.1%), 1 (2.6%) due to insufficient clinical response. Most common AEs overall (N=156) leading to dose reduction were diarrhea (26.3%), increased alanine (ALT; 13.5%) and aspartate (10.3%) aminotransferase. Most common (≥20%) AEs before dose reduction to each dose were diarrhea, nausea, vomiting, increased ALT and headache; tolerability improved after dose reduction—most common AEs decreased by >10%, except increased ALT.

Conclusion
BOS dose reduction in pts with CP CML with resistance or intolerance to prior TKIs improved tolerability. Resistant pts were generally treated with higher doses of BOS than intolerant pts. Individualized tx allowed pts to remain on BOS while maintaining efficacy. The 500 mg QD dose of BOS should be used if tolerated, while lower doses should be reserved for when tx tolerability is a concern. Temporary BOS dose reduction is an important strategy to manage AEs; nevertheless, given the limited amount of data available, dose adjustments in intolerant and particularly in resistant pts should be made with caution and based on individual pt and disease characteristics.  

Session topic: 8. Chronic myeloid leukemia - Clinical

Keyword(s): Chronic myeloid leukemia, Tyrosine kinase inhibitor

Abstract: PF415

Type: Poster Presentation

Presentation during EHA24: On Friday, June 14, 2019 from 17:30 - 19:00

Location: Poster area

Background
Bosutinib (BOS) is approved in patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) who are newly diagnosed (400 mg once daily [QD]) or resistant or intolerant to prior treatment (tx; 500 mg QD). Some pts require dose interruptions/reductions to manage the occurrence of adverse events (AEs).

Aims
Evaluate efficacy and safety of BOS before and after dose reductions in pretreated pts with Ph+ chronic phase (CP) CML.

Methods
BYOND is an ongoing, single-arm, open-label phase 4 study of BOS in pts resistant or intolerant to prior tyrosine kinase inhibitors (TKIs). Dose reduction to 400, 300 or 200 mg QD was allowed for management of tx-related AEs.

Results
Pts with Ph+ CP CML (N=156) were categorized as resistant to ≥1 prior TKI (n=83; 53.2%) or intolerant to all prior TKIs (73; 46.8%); data cutoff: 1 y after last enrolled pt. Overall, median (range) tx duration was 23.7 (0.2–42.2) mo and median (range) dose intensity was 313.1 (79.7–560.6) mg/d. In resistant and intolerant pts, median (range) tx duration was similar: 23.4 (0.2–42.2) and 25.3 (0.4–41.9) mo, respectively. 37.3% resistant and 63.0% intolerant pts experienced dose reductions to 300 or 200 mg QD. This resulted in higher median dose intensity in resistant vs intolerant pts: 405.9 (125.0–560.6) vs 292.0 (79.7–500.0) mg/d. 153 pts started at 500 mg QD or reduced to a lower dose, ≥1 dose reduction to 400, 300 and 200 mg QD, respectively, was seen in 42 (27.5%), 39 (25.5%) and 38 (24.8%) and median (range) tx duration was 27.6 (0.4–42.2), 11.1 (0.8–41.3) and 24.0 (0.9–41.9) mo. Of 34 pts who remained on 500 mg QD without dose reduction, median (range) tx duration was 23.5 (0.2–41.4) mo; 21 (61.8%) had complete cytogenetic response; 19 (55.9%) had major molecular response (MMR). Among pts who dose-reduced, most had a newly attained or maintained response, few pts lost a previously attained response (Table). Of 10 pts with baseline mutations, 7 (70.0%) received 400 or 500 mg QD; 3 (30.0%) achieved at least MMR. Across all time points up to 2 y, a high proportion (>65%) of resistant pts still receiving tx were on 400 or 500 mg QD while ~20% of intolerant pts still receiving tx were on 500 mg QD. Tx was discontinued in 17 (50.0%), 12 (28.6%), 24 (61.5%) and 15 (39.5%) pts without dose reduction, ≥1 dose reduction to 400, 300 and 200 mg QD, respectively, including: 4 (11.8%), 7 (16.7%), 17 (43.6%), 11 (28.9%) due to AEs; and 5 (14.7%), 0, 2 (5.1%), 1 (2.6%) due to insufficient clinical response. Most common AEs overall (N=156) leading to dose reduction were diarrhea (26.3%), increased alanine (ALT; 13.5%) and aspartate (10.3%) aminotransferase. Most common (≥20%) AEs before dose reduction to each dose were diarrhea, nausea, vomiting, increased ALT and headache; tolerability improved after dose reduction—most common AEs decreased by >10%, except increased ALT.

Conclusion
BOS dose reduction in pts with CP CML with resistance or intolerance to prior TKIs improved tolerability. Resistant pts were generally treated with higher doses of BOS than intolerant pts. Individualized tx allowed pts to remain on BOS while maintaining efficacy. The 500 mg QD dose of BOS should be used if tolerated, while lower doses should be reserved for when tx tolerability is a concern. Temporary BOS dose reduction is an important strategy to manage AEs; nevertheless, given the limited amount of data available, dose adjustments in intolerant and particularly in resistant pts should be made with caution and based on individual pt and disease characteristics.  

Session topic: 8. Chronic myeloid leukemia - Clinical

Keyword(s): Chronic myeloid leukemia, Tyrosine kinase inhibitor

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies